Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localization signals . On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription . .

NF-kappa-B inhibitor alpha (I-kappa-B-alpha) (IkB-alpha) (IkappaBalpha) (Major histocompatibility complex enhancer-binding protein MAD3),NFKBIA IKBA MAD3 NFKBI

P25963,Q9Z1E3,Q63746

4792/18035/25493

Human,Mouse,Rat

WB,IHC,IF,ICC,ELISA

WB 1:1000-5000
IHC 1:100-400
IF 1:100-1:400
ICC 1:100-1:400
ELISA 1:5000-1:20000

IκB-α (Phospho Ser36) Monoclonal Antibody detects endogenous levels of IκB-α only when phosphorylated at Ser36.and dually phosphorylated at two sites.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):LDsMK

39kDa

Rabbit

Monoclonal

N642

IgG,Kappa

Protein A

PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

Store at -20℃. Stable for 12 months from date of receipt.